Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia

Wayne, A. S., Huynh, V., Hijiya, N., Rouce, R. H., Brown, P. A., Krueger, J., Kitko, C. L., Ziga, E. D., Hermiston, M. L., Richards, M. K., Baruchel, A., Schuberth, P. C., Rossi, J., Zhou, L., Goyal, L., Jain, R., Vezan, R., Masouleh, B. K., & Lee, D. W. (2022). Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. Haematologica, 108(3), 747–760. https://doi.org/10.3324/haematol.2022.280678
Authors:
Alan S Wayne
Van Huynh
Nobuko Hijiya
Rayne H Rouce
Patrick A Brown
Joerg Krueger
Carrie L Kitko
Edward Dela Ziga
Michelle L Hermiston
Michael K Richards
Andre Baruchel
Petra C Schuberth
John Rossi
Lang Zhou
Lovely Goyal
Rajul Jain
Remus Vezan
Behzad Kharabi Masouleh
Daniel W Lee
Affiliated Authors:
Nobuko Hijiya
Columbia Affiliation:
Subjects:
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
Epidemiology and Treatment of Childhood Leukemia (OpenAlex Topic)
Hematopoietic Stem Cell Transplantation (MeSH)
Lymphoma, B-Cell (MeSH)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (MeSH)
Receptors, Chimeric Antigen (MeSH)
elink
Publication Type:
Article
Unique ID:
10.3324/haematol.2022.280678
PMID:
36263840
DOI:
10.3324/haematol.2022.280678
Journal:
Haematologica
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View OpenAlex Record

Record Created: